Ellis et al., Nature, 292:506-511, Aug. 1981. Goldfarb et al., Nature, 296:404–409, Apr. 1981. Huang et al., Cell, 27:245-255, Dec. 1981. Blair et al., Science, 212:941-943, 1981. Der et al., Proc. Natl. Acad. Sci. USA, 79:3637-3640, Jun. 1982. Shih et al., Cell, 29:161-169, 1982. Gorman et al., Proc. Natl. 79:6777-6781, Nov. 1982. Schwab et al., EPA-600/9-82-013, Sym: Carcinogen, Polynucl. Aromat. Hydrocarbons Mar. Environ., 212-32, (1982). Wagner et al., (1981), Proc. Natl. Acad. Sci. USA, 78, 5016-5020. Stewart et al., (1982), Science, 217, 1046-8. Costantini et al., (1981), Nature, 294, 92-94. Lacy et al., (1983), Cell, 34, 343-358. McKnight et al., (1983), Cell, 34, 335. Binster et al., (1983), Nature, 306, 332–336. Palmiter et al., (1982), Nature, 300, 611-615. Palmiter et al., (1983), Science, 222,814. Palmiter et al., (1982), Cell, 29, 701-710.

Blair et al, Science 212:941-943, 1981. Der et al, Proc. Natl. Acad. Sci., USA 79:3637-3640, Jun., 1982. Shih et al, Cell 29:161-169, 1982. Gorman et al, Proc. Natl. 79:6777-6781, Nov. 1982. Schwab et al, EPA-600/9-82-013, Sym: Carcinogen, Polynucl. Aromat. Hydrocarbons Mar. Environ, 212-32 (1982). Wagner et al. (1981) Proc. Natl. Acad. Sci USA 78, 50165020, Stewart et al. (1982) Science 217, 1046-8. Costantini et al. (1981) Nature 294,92-94. Lacy et al. (1983) Cell 34, 343-358. McKnight et al. (1983) Cell 34, 335. Binster et al. (1983) Nature 306, 332-336. Palmiter et al. (1982) Nature 300, 611-615. Palmiter et al. (1983) Science 222,814. Palmiter et al. (1982) Cell 29, 701-710.

Hormonal control of metabolic rate can be important in regulating the imbalance between energy intake and expenditure that underlies the development of obesity. In mice fed a high-fat diet, human fibroblast growth factor 19 (FGF19) increased metabolic rate [1.53 +/- 0.06 liters O(2)/h.kg(0.75) (vehicle) vs. 1.93 +/- 0.05 liters O(2)/h.kg(0.75) (FGF19); P < 0.001] and decreased respiratory quotient [0.82 +/- 0.01 (vehicle) vs. 0.80 +/- 0.01 (FGF19); P < 0.05]. In contrast to the vehicle-treated mice that gained weight (0.14 +/- 0.05 g/mouse.d), FGF19-treated mice lost weight (-0.13 +/- 0.03 g/mouse.d; P < 0.001) without a significant change in food intake. Furthermore, in addition to a reduction in weight gain, treatment with FGF19 prevented or reversed the diabetes that develops in mice made obese by genetic ablation of brown adipose tissue or genetic absence of leptin. To explore the mechanisms underlying the FGF19-mediated increase in metabolic rate, we profiled the FGF19-induced gene expression changes in the liver and brown fat. In brown adipose tissue, chronic exposure to FGF19 led to a gene expression profile that is consistent with activation of this tissue. We also found that FGF19 acutely increased liver expression of the leptin receptor (1.8-fold; P < 0.05) and decreased the expression of acetyl coenzyme A carboxylase 2 (0.6-fold; P < 0.05). The gene expression changes were consistent with the experimentally determined increase in fat oxidation and decrease in liver triglycerides. Thus, FGF19 is able to increase metabolic rate concurrently with an increase in fatty acid oxidation.

Indirect evidence suggests that type-I interferons (IFN-alpha/beta) play a significant role in the pathogenesis of lupus. To directly examine the contribution of these pleiotropic molecules, we created congenic NZB mice lacking the alpha-chain of IFN-alpha/betaR, the common receptor for the multiple IFN-alpha/beta species. Compared with littermate controls, homozygous IFN-alpha/betaR-deleted NZB mice had significantly reduced anti-erythrocyte autoantibodies, erythroblastosis, hemolytic anemia, anti-DNA autoantibodies, kidney disease, and mortality. These reductions were intermediate in the heterozygous-deleted mice. The disease-ameliorating effects were accompanied by reductions in splenomegaly and in several immune cell subsets, including B-1 cells, the major producers of anti-erythrocyte autoantibodies. Decreases of B and T cell proliferation in vitro and in vivo, and of dendritic cell maturation and T cell stimulatory activity in vitro were also detected. Absence of signaling through the IFN-alpha/betaR, however, did not affect increased basal levels of the IFN-responsive p202 phosphoprotein, encoded by a polymorphic variant of the Ifi202 gene associated with the Nba2 predisposing locus in NZB mice. The data indicate that type-I IFNs are important mediators in the pathogenesis of murine lupus, and that reducing their activity in the human counterpart may be beneficial.

Therapeutic antibodies directed against tumor necrosis factor alpha (TNF-α) for the treatment of rheumatoid arthritis, and against the human EGF receptor-2 (HER2) receptor for the treatment of breast cancer have provided significant clinical benefit for the patients. The success of these antibodies has also provided strong support for the possibility that increased activity of cytokines or growth factors is causally implicated in a variety of human diseases. Interferon alpha (IFN-α) is induced by viruses (linked by epidemiological studies to autoimmune diseases), has significant direct effects on both epithelial cells and the immune system, and then can be further induced by the autoantibodies and apoptotic cells generated by the actions of IFN-α. The direct and deleterious impact on target tissues, the ability to induce an autoimmune response, and the potential for a self-sustaining cycle of induction and damage suggests that IFN-α could be a pivotal factor in the development of autoimmune diseases. This review will evaluate the rationale for, possible approaches to, and safety concerns associated with, targeting interferon alpha (IFN-α) as a therapeutic strategy for the treatment of autoimmune diseases. While the approach may be applicable to several autoimmune diseases, there will be an emphasis on systemic lupus erythematosus and insulin dependent diabetes mellitus.